Home LiteratureArticle Details
PMID: 10887512 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Role of TGF beta in the anti-estrogen response/resistance of human breast cancer.

Journal of mammary gland biology and neoplasia ·Vol. 1 ·No. 4 ·1996-10-00 ·Pages 381-9

Benson JR, Baum M, Colletta AA

Abstract

Transforming growth factor beta (TGF beta) has potent inhibitory effects upon epithelial proliferation and malignant progression may be associated with breakdown of the autocrine and paracrine inhibitory loops in which TGF beta participates. The therapeutic effecs of anti-estrogens may be partially attributable to boosting of local endogenous levels of TGF beta. This article reviews the evidence in support of TGF beta being a proximate effector in mediation of the anti-neoplastic effects of anti-estrogens. Both the conventional estrogen receptor (ER) dependent and ER independent mechanisms of action are likely to be involved. Evidence for preferential stromal induction of TGF beta by anti-estrogens is emphasized, together with the therapeutic potential of this strategy for improving outcome in early breast cancer irrespective of ER status.

MeSH Terms
Autocrine Communication Breast Neoplasms/drug therapy,metabolism,pathology Drug Resistance, Neoplasm Estrogen Antagonists/therapeutic use Estrogens/metabolism Female Humans Neoplasms, Hormone-Dependent/drug therapy,metabolism,pathology Paracrine Communication Transforming Growth Factor beta/metabolism
Chemicals
Estrogen Antagonists Estrogens Transforming Growth Factor beta
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Benson J R
Hartwell Laboratory, Institute of Cancer Research, United Kingdom.
Baum M
Colletta A A
References (41)
41 references, click to expand
  1. Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues.
    Anticancer Res. 1990 Sep-Oct;10(5A):1115-26 PMID: 1978632
  2. Desmoid tumours treated with triphenylethylenes.
    Eur J Cancer. 1992;28A(6-7):1014-8 PMID: 1385717
  3. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.
    Cancer Res. 1992 Dec 15;52(24):6949-52 PMID: 1458485
  4. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.
    Br J Cancer. 1988 Jun;57(6):608-11 PMID: 2900647
  5. Absence of transforming growth factor-beta responsiveness in the tamoxifen growth-inhibited human breast cancer cell line CAMA-1.
    J Cell Biochem. 1994 Mar;54(3):332-42 PMID: 8200913
  6. Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor.
    Biochem Biophys Res Commun. 1986 Oct 30;140(2):523-9 PMID: 3778464
  7. Stromal-epithelial interactions in normal and abnormal prostatic development.
    Prog Clin Biol Res. 1987;239:251-72 PMID: 3309957
  8. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.
    Proc Natl Acad Sci U S A. 1987 Aug;84(16):5788-92 PMID: 2886992
  9. Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells.
    Br J Cancer. 1995 Dec;72 (6):1441-6 PMID: 8519657
  10. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene.
    Proc Natl Acad Sci U S A. 1987 Feb;84(3):837-41 PMID: 2880347
  11. Distribution and modulation of the cellular receptor for transforming growth factor-beta.
    J Cell Biol. 1987 Aug;105(2):965-75 PMID: 2887577
  12. The prognostic significance of transforming growth factors in human breast cancer.
    Br J Cancer. 1993 Jun;67(6):1408-12 PMID: 8390290
  13. TGF-beta: regulation of extracellular matrix.
    Kidney Int. 1992 Mar;41(3):557-9 PMID: 1573828
  14. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice.
    Cell Growth Differ. 1993 Mar;4(3):193-201 PMID: 8466857
  15. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts.
    Br J Cancer. 1990 Sep;62(3):405-9 PMID: 1698443
  16. Localization of transforming growth factor-beta isotypes in lesions of the human breast.
    Hum Pathol. 1992 Jan;23(1):13-20 PMID: 1544664
  17. 8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer.
    Breast Cancer Res Treat. 1986;7(2):59-70 PMID: 3013348
  18. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018.
    Endocrinology. 1985 Oct;117(4):1409-17 PMID: 4029083
  19. Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells.
    Cancer Res. 1988 Jul 15;48(14):3898-904 PMID: 3164252
  20. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
    Lancet. 1992 Jan 4;339(8784):1-15 PMID: 1345950
  21. Autocrine secretion--10 years later.
    Ann Intern Med. 1992 Sep 1;117(5):408-14 PMID: 1503333
  22. Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor beta.
    Biochem J. 1993 Aug 15;294 ( Pt 1):109-12 PMID: 8363560
  23. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells.
    Cell. 1987 Feb 13;48(3):417-28 PMID: 2879636
  24. Transforming growth factor beta isoforms in breast cancer.
    Br J Cancer. 1994 Dec;70(6):1278-9 PMID: 7981090
  25. Type beta transforming growth factor: a bifunctional regulator of cellular growth.
    Proc Natl Acad Sci U S A. 1985 Jan;82(1):119-23 PMID: 3871521
  26. The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta.
    J Clin Invest. 1991 Jan;87(1):277-83 PMID: 1985102
  27. Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer.
    Br J Cancer. 1991 Apr;63(4):609-14 PMID: 2021547
  28. Role of transforming growth factor-beta in the development of the mouse embryo.
    J Cell Biol. 1987 Dec;105(6 Pt 2):2861-76 PMID: 3320058
  29. Autocrine growth factors and cancer.
    Nature. 1985 Feb 28-Mar 6;313(6005):745-7 PMID: 3883191
  30. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh.
    Lancet. 1987 Jul 25;2(8552):171-5 PMID: 2885637
  31. Growth factor expression in normal, benign, and malignant breast tissue.
    Br Med J (Clin Res Ed). 1988 Jun 11;296(6637):1621-4 PMID: 3135043
  32. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor.
    Ann Surg. 1995 Aug;222(2):155-62 PMID: 7543740
  33. Expression of transforming growth factor beta mRNA isoforms in human breast cancer.
    Br J Cancer. 1994 Jun;69(6):1006-9 PMID: 8198961
  34. Inhibition of angiogenesis by antiestrogens.
    Cancer Res. 1993 Feb 1;53(3):533-5 PMID: 7678775
  35. Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen.
    Br J Cancer. 1996 Aug;74(3):352-8 PMID: 8695348
  36. Alternative mechanisms of action of anti-oestrogens.
    Breast Cancer Res Treat. 1994;31(1):5-9 PMID: 7981456
  37. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment.
    Cancer Res. 1992 Aug 1;52(15):4261-4 PMID: 1322240
  38. Complex regulation of TGF beta expression by retinoic acid in the vitamin A-deficient rat.
    Development. 1991 Apr;111(4):1081-6 PMID: 1879351
  39. Post-transcriptional regulation of the human transforming growth factor-beta 1 gene.
    J Biol Chem. 1992 Jul 5;267(19):13702-7 PMID: 1618868
  40. Occurrence of a fetal fibroblast phenotype in familial breast cancer.
    Int J Cancer. 1986 Jun 15;37(6):831-6 PMID: 3710614
  41. Retinoic acid induces transforming growth factor-beta 2 in cultured keratinocytes and mouse epidermis.
    Cell Regul. 1989 Nov;1(1):87-97 PMID: 2519621
Article Info
Journal
Journal of mammary gland biology and neoplasia
Abbr.
J Mammary Gland Biol Neoplasia
ISSN
1083-3021
DOI
10.1007/BF02017394
Published
1996-10-00
Pages
381-9
Language
English
Region
United States
NLM ID
9601804
Subset
IM
External Links
PubMed source DOI: 10.1007/BF02017394 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2